Analysts Anticipate LeMaitre Vascular Inc (NASDAQ:LMAT) Will Post Earnings of $0.21 Per Share

Share on StockTwits

Wall Street brokerages expect that LeMaitre Vascular Inc (NASDAQ:LMAT) will report earnings per share of $0.21 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular reported earnings per share of $0.43 in the same quarter last year, which would suggest a negative year over year growth rate of 51.2%. The company is expected to report its next earnings report on Thursday, July 25th.

On average, analysts expect that LeMaitre Vascular will report full-year earnings of $0.83 per share for the current financial year, with EPS estimates ranging from $0.82 to $0.84. For the next year, analysts anticipate that the company will post earnings of $0.92 per share, with EPS estimates ranging from $0.89 to $0.95. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 EPS for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.02). The business had revenue of $28.48 million for the quarter, compared to analysts’ expectations of $27.94 million. LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 earnings per share.

A number of brokerages have recently commented on LMAT. Barrington Research reissued a “buy” rating and issued a $32.00 price target on shares of LeMaitre Vascular in a report on Thursday, May 2nd. ValuEngine lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Thursday, April 18th. BidaskClub lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Finally, Zacks Investment Research lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. LeMaitre Vascular currently has a consensus rating of “Hold” and an average target price of $31.00.

Large investors have recently bought and sold shares of the company. Bank of Montreal Can lifted its position in shares of LeMaitre Vascular by 99.1% in the 4th quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 554 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of LeMaitre Vascular by 66,640.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 3,332 shares during the period. Municipal Employees Retirement System of Michigan purchased a new stake in shares of LeMaitre Vascular in the 4th quarter worth about $106,000. Metropolitan Life Insurance Co. NY lifted its position in LeMaitre Vascular by 373.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 4,441 shares during the period. Finally, Oregon Public Employees Retirement Fund purchased a new position in LeMaitre Vascular during the 4th quarter valued at about $143,000. 77.10% of the stock is owned by hedge funds and other institutional investors.

Shares of LMAT stock opened at $27.26 on Monday. The stock has a market cap of $542.14 million, a PE ratio of 26.25, a P/E/G ratio of 2.77 and a beta of 1.17. The company’s 50 day simple moving average is $26.91. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99.

The business also recently announced a quarterly dividend, which was paid on Thursday, June 6th. Stockholders of record on Wednesday, May 22nd were given a $0.085 dividend. The ex-dividend date was Tuesday, May 21st. This represents a $0.34 annualized dividend and a dividend yield of 1.25%. LeMaitre Vascular’s dividend payout ratio is 40.48%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Read More: Percentage Gainers

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Transcontinental Expected to Post Q3 2019 Earnings of $0.53 Per Share
Transcontinental Expected to Post Q3 2019 Earnings of $0.53 Per Share
Q3 2019 EPS Estimates for Franco Nevada Corp Raised by Raymond James
Q3 2019 EPS Estimates for Franco Nevada Corp Raised by Raymond James
Q3 2019 EPS Estimates for Continental Resources, Inc. Decreased by Jefferies Financial Group
Q3 2019 EPS Estimates for Continental Resources, Inc. Decreased by Jefferies Financial Group
Equities Analysts Set Expectations for Eni SpA’s Q3 2019 Earnings
Equities Analysts Set Expectations for Eni SpA’s Q3 2019 Earnings
Jefferies Financial Group Weighs in on Taubman Centers, Inc.’s Q3 2019 Earnings
Jefferies Financial Group Weighs in on Taubman Centers, Inc.’s Q3 2019 Earnings
William Blair Analysts Increase Earnings Estimates for BioDelivery Sciences International, Inc.
William Blair Analysts Increase Earnings Estimates for BioDelivery Sciences International, Inc.


© 2006-2019 Ticker Report